Idursulfase
From Wikipedia, the free encyclopedia
| Clinical data | |
|---|---|
| AHFS/Drugs.com | monograph |
| Legal status | ? |
| Identifiers | |
| CAS number | 50936-59-9  |
| ATC code | A16AB09 |
| DrugBank | DB01271 |
| UNII | 5W8JGG2651 |
| KEGG | D04499 |
| ChEMBL | CHEMBL1201826  |
| Chemical data | |
| Formula | ? |
| (what is this?) (verify) | |
Idursulfase (brand name Elaprase), manufactured by Shire, is a drug used to treat Hunter syndrome (also called MPS-II).[1] It is a purified form of the lysosomal enzyme iduronate-2-sulfatase and is produced by recombinant DNA technology in a human cell line.
It is one of the most expensive drugs ever produced, costing US$375,000 per patient per year.[2][3]
References
- ↑ Garcia AR, DaCosta JM, Pan J, Muenzer J, Lamsa JC (2007). "Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II". Mol. Genet. Metab. 91 (2): 183–90. doi:10.1016/j.ymgme.2007.03.003. PMID 17459751.
- ↑ "Drug approved to treat rare but potentially deadly disease". Retrieved 2011-04-29.
- ↑ Health Care: The World's Most Expensive Drugs, Matthew Herper, Forbes, Feb. 22, 2010
External links
- idursulfase at the US National Library of Medicine Medical Subject Headings (MeSH)
| ||||||||||||||||
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.